Hemophilia is a genetic disease that stems from the deficiency of a protein required for normal blood clotting – clotting factor VIII in hemophilia A or clotting factor IX in hemophilia B. As the ...

The hemophilia market is expected to experience significant growth due to advancements in gene therapy, innovative treatments, and an increasing focus on personalized medicine. Rising awareness and ...

The government has set aside £11.8bn to compensate victims of the infected blood scandal, after a public inquiry found the ...

Novo Nordisk’s haemophilia A therapy Mim8 stopped bleeding completely in 74.3% of children in a Phase III trial. The ...

Novo Nordisk has shared positive results from a late-stage study of its investigational haemophilia A therapy Mim8 in patients aged one to 11 years.

That was before the spectacular success of Hemlibra, a bispecific antibody-based drug that mimics the function of Factor VIII by bridging clotting factors on either side of it in the clotting pathway.

Did you know that your blood type could play a much bigger role in your health than you thought? While cardiovascular risks are often associated with factors such as diet, smoking, and physical ...

Sobi’s Sanofi-partnered efanesoctocog alfa has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA ...

The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.

People with haemophilia A have a shortage of a clotting agent called Factor VIII, while people with haemophilia B do not have enough Factor IX. In the 1970s, a new treatment using donated human ...

specifically in clotting factors VIII or IX. While it is not yet a cure, it is at least providing long-term expression,” said von Drygalski. The treatment involves a one-time infusion of Hemgenix, a ...